Lexicon Pharmaceuticals Avoids Delisting with New Nasdaq Bid-Price Grace Period

Rhea-AI Filing Summary

Lexicon Pharmaceuticals, Inc. (LXRX) disclosed in an 8-K filing that on July 3, 2025 it received written notice from Nasdaq Listing Qualifications granting the company an additional 180-day grace period—until December 30, 2025—to regain compliance with the $1.00 minimum bid-price requirement for continued listing. To secure the extension, Lexicon applied to transfer its shares from the Nasdaq Global Select Market to the Nasdaq Capital Market; Nasdaq has approved the transfer, which will become effective at the opening of trading on July 7, 2025.

During the second compliance period, the company must deliver a closing bid price of at least $1.00 for 10 consecutive business days. Eligibility for the extension remains contingent on meeting all initial Capital Market listing standards—except the bid price—and providing written confirmation that Lexicon intends to cure the deficiency, which may include effecting a reverse stock split if necessary.

The notice prevents an immediate delisting but underlines the ongoing risk that LXRX shares could be removed from Nasdaq if compliance is not restored by year-end. Investors should monitor management’s plans—particularly any potential reverse split—and the stock’s trading performance over the coming months.

Positive

• Additional 180-day compliance period postpones delisting and preserves access to Nasdaq-based liquidity and visibility.
• Transfer to Nasdaq Capital Market approved, ensuring continued listing while the company works toward bid-price compliance.

Negative

• Continued breach of the $1 minimum bid requirement underscores ongoing market-valuation challenges and potential investor concern.
• Possible need for a reverse stock split could signal weakness and may dilute perceived value if fundamentals do not improve.

Insights

Financial Analyst

TL;DR: Extension avoids immediate delisting but highlights valuation pressure; overall impact modestly negative.

Nasdaq’s 180-day extension keeps liquidity and index eligibility intact, sparing shareholders the disruption of an involuntary delisting. However, the core issue—LXRX’s sub-$1 price—remains unresolved. Moving down to the Capital Market lowers listing thresholds and may signal weakness to institutional investors accustomed to Global Select standards. A reverse split, while mechanically restoring price, can compress float and sometimes precede further declines if not coupled with operational improvements. Absent operating updates or capital-raising news, the filing primarily reflects continued valuation strain. Impact: mildly negative until tangible progress toward compliance is evident.

Corporate Governance Expert

TL;DR: Governance response appropriate; risk moderate; extension offers structured path to compliance.

Management followed prescribed governance protocols—applying for market transfer, providing formal intent to cure, and disclosing promptly via an 8-K. The Capital Market’s requirements better fit Lexicon’s current capitalization, reducing immediate delisting risk. Shareholder value preservation hinges on transparent communication of any reverse-split timetable and continued adherence to market-value-of-public-float thresholds. From a governance standpoint, the board’s willingness to act swiftly and maintain listing optionality is constructive, though success depends on execution.

0001062822FALSE00010628222024-11-222024-11-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________

FORM 8-K

__________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 3, 2025

Lexicon Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware			000-30111			76-0474169
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(I.R.S. Employer Identification Number)

2445 Technology Forest Blvd., 11th Floor

The Woodlands, Texas 77381

(Address of principal executive offices and Zip Code)

(281) 863-3000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.001			LXRX			The Nasdaq Global Select Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On July 3, 2025, we received a letter from the Listing Qualifications staff of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that we are eligible for an additional 180-calendar day period, or until December 30, 2025, in which to regain compliance with Nasdaq's minimum $1 bid price requirement for our common stock. In order to regain compliance with the minimum bid price requirement, the closing bid price of our common stock must be at least $1 per share for a minimum of ten consecutive business days during this additional 180-calendar day period.

In order to be eligible for the additional compliance period, we applied to transfer our common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. Nasdaq approved such application, and our common stock will be transferred to the Capital Market at the opening of business on July 7, 2025.

Our eligibility for the additional compliance period is subject to the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market (with the exception of the bid price requirement), written notice of our intent to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary, and additional supporting information provided in our transfer application.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Lexicon Pharmaceuticals, Inc.
Date: July 3, 2025			By:			/s/ Brian T. Crum
						Brian T. Crum
						Senior Vice President and General Counsel

FAQ

Why did Lexicon Pharmaceuticals (LXRX) file this 8-K?

The company reported receiving a Nasdaq notice granting an additional 180-day period to regain compliance with the $1 minimum bid price rule.

What is the new deadline for LXRX to meet Nasdaq’s $1 bid price?

Lexicon must achieve a closing bid price of at least $1.00 for 10 consecutive business days by December 30, 2025.

What market will LXRX trade on after July 7, 2025?

The stock will transfer from the Nasdaq Global Select Market to the Nasdaq Capital Market.

Could Lexicon perform a reverse stock split?

Yes. Management indicated it may effect a reverse split if needed to cure the bid-price deficiency.

What happens if LXRX fails to regain compliance by the deadline?

The shares would be subject to delisting from Nasdaq, reducing liquidity and investor access.